ES2156305T3 - Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen. - Google Patents

Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen.

Info

Publication number
ES2156305T3
ES2156305T3 ES96942574T ES96942574T ES2156305T3 ES 2156305 T3 ES2156305 T3 ES 2156305T3 ES 96942574 T ES96942574 T ES 96942574T ES 96942574 T ES96942574 T ES 96942574T ES 2156305 T3 ES2156305 T3 ES 2156305T3
Authority
ES
Spain
Prior art keywords
optionally replaced
rent
optionally
pharmacos
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96942574T
Other languages
English (en)
Inventor
Hironori Harada
Jun-Ichi Kazami
Susumu Watanuki
Ryuji Tsuzuki
Katsumi Sudou
Akihiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2156305T3 publication Critical patent/ES2156305T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

NUEVOS DERIVADOS ARILETENSULFONAMIDA QUE TIENEN UNA ELEVADA AFINIDAD POR LOS FARMACOS, ESPECIALMENTE RECEPTORES DE LA ENDOSERINA Y REPRESENTADOS POR LA FORMULA GENERAL (I): SALES FARMACOLOGICAMENTE DE LOS MISMOS Y FARMACOS QUE CONTIENEN LOS MISMOS COMO INGREDIENTE ACTIVO, ESPECIALMENTE ANTAGONISTAS DEL RECEPTOR DE LA ENDOSERINA, EN LA QUE AR REPRESENTA ARILO OPCIONALMENTE SUSTITUIDO O HETEROARILO DE CINCO O SEIS ESLABONES OPCIONALMENTE SUSTITUIDO; X REPRESENTA OXIGENO, AZUFRE O EL GRUPO REPRESENTADO POR - NH -; Y REPRESENTA OXIGENO O AZUFRE; R 1 REPRESENTA HIDROGENO, ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO CON HALOGENO, CICLOALQUILO, ARILO OPCIONALMENTE SUSTITUIDO O HETEROARILO DE CINCO O SEIS ESLABONES OPCIONALMENTE SUSTITUIDO; R 2 REPRESENTA ALQUILO INFERIOR, ALQUENILO INFERIOR O ALQUINILO INFERIOR, CADA UNO DE ELLOS OPCIONALMENTE SUSTITUIDO CON UNO A TRES GRUPOS SELECCIONADOS ENTRE HIDROXI, ALCOXIS INFERIORES, CICLOALQUILOS, HALOGENOS, CARBOXI Y ALCOXICARBONILOS INFERIORES; R 3 REPRESENTA FENILO OPCIONALMENTE SUSTIT UIDO CON UNO A CUATRO GRUPOS SELECCIONADOS ENTRE ALQUILOS INFERIORES OPCIONALMENTE HALOGENADOS, ALCOXIS INFERIORES, HALOGENOS, TIOALQUILOS INFERIORES, ALQUILSULFINILOS INFERIORES, ALCANSULFONILOS INFERIORES CARBOXI, ALCOXICARBONILOS INFERIORES Y CARBAMOILO; Y R 4 Y R 5 SON IGUALES O DIFERENTES Y CADA UNO DE ELLOS REPRESENTA HIDROGENO O ALQUILO INFERIOR.
ES96942574T 1995-12-20 1996-12-19 Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen. Expired - Lifetime ES2156305T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33211195 1995-12-20

Publications (1)

Publication Number Publication Date
ES2156305T3 true ES2156305T3 (es) 2001-06-16

Family

ID=18251283

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96942574T Expired - Lifetime ES2156305T3 (es) 1995-12-20 1996-12-19 Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen.

Country Status (14)

Country Link
US (1) US6083955A (es)
EP (1) EP0882719B1 (es)
JP (1) JP3087968B2 (es)
KR (1) KR100456650B1 (es)
CN (1) CN1102580C (es)
AT (1) ATE201202T1 (es)
AU (1) AU703386B2 (es)
BR (1) BR9612061A (es)
DE (1) DE69612874T2 (es)
ES (1) ES2156305T3 (es)
HU (1) HUP0000474A3 (es)
RU (1) RU2172735C2 (es)
TW (1) TW414792B (es)
WO (1) WO1997022595A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ES2241133T3 (es) 1997-04-28 2005-10-16 Encysive Pharmaceuticals Inc. Sulfamidas para el tratamiento de los trastornos inducidos por la endotelina.
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
WO2001046156A1 (en) * 1999-12-22 2001-06-28 Actelion Pharmaceuticals Ltd. Butyne diol derivatives
IL150311A0 (en) 1999-12-31 2002-12-01 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB0003234D0 (en) * 2000-02-11 2000-04-05 Pfizer Ltd Method of treatment
EP1256344B1 (en) * 2000-02-16 2006-12-20 Astellas Pharma Inc. Remedies for endothelin-induced diseases
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
GB0023074D0 (en) * 2000-09-20 2000-11-01 Pfizer Ltd Pyridazines
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US7091201B2 (en) * 2000-09-25 2006-08-15 Actelion Pharmaceuticals Ltd. Arylalkane-sulfonamides having endothelin-antagonist activity
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
NZ525614A (en) 2000-12-18 2005-03-24 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
WO2002064143A1 (fr) * 2001-02-09 2002-08-22 Yamanouchi Pharmaceutical Co., Ltd. Composition medicale pour le traitement de l'insuffisance cardiaque chronique
CA2443042A1 (en) * 2001-04-03 2002-10-17 Atsuo Tahara Novel use of arylethene sulfonamide derivatives
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
WO2002083142A1 (fr) * 2001-04-13 2002-10-24 Yamanouchi Pharmaceutical Co., Ltd. Nouvelle utilisation du derive arylethenesulfonamide
CA2452253C (en) * 2001-07-27 2009-06-02 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of arylethenesulfonamide derivative and preparation process thereof
WO2003055863A1 (en) * 2002-01-02 2003-07-10 Actelion Pharmaceuticals Ltd Novel alkansulfonamides as endothelin antagonists
JP4769460B2 (ja) 2002-12-02 2011-09-07 アクテリオン ファーマシューティカルズ リミテッド 新規スルファミド類
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ549535A (en) 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
DK1928409T3 (da) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
US20100256371A1 (en) * 2009-04-02 2010-10-07 Glenmark Processes for the preparation of bosentan and its intermediates thereof
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
CN112778215B (zh) * 2021-01-29 2023-06-20 中国医科大学 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用
CN112898208B (zh) * 2021-01-29 2023-06-20 中国医科大学 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5222003A (en) * 1975-08-13 1977-02-19 Hitachi Ltd Process for removing hydrogen sulfide from hot gas
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (es) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (es) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
JPH07332111A (ja) * 1994-06-07 1995-12-22 Nippon Muki Co Ltd 吸気フィルタ装置

Also Published As

Publication number Publication date
US6083955A (en) 2000-07-04
KR20000064423A (ko) 2000-11-06
AU1171097A (en) 1997-07-14
KR100456650B1 (ko) 2005-06-20
ATE201202T1 (de) 2001-06-15
DE69612874D1 (de) 2001-06-21
EP0882719A1 (en) 1998-12-09
BR9612061A (pt) 1999-02-23
CN1204326A (zh) 1999-01-06
CN1102580C (zh) 2003-03-05
WO1997022595A1 (fr) 1997-06-26
RU2172735C2 (ru) 2001-08-27
AU703386B2 (en) 1999-03-25
HUP0000474A2 (hu) 2000-12-28
EP0882719B1 (en) 2001-05-16
JP3087968B2 (ja) 2000-09-18
HUP0000474A3 (en) 2001-06-28
TW414792B (en) 2000-12-11
DE69612874T2 (de) 2001-10-04
EP0882719A4 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
ES2156305T3 (es) Derivados de ariletenosulfonamida y composiciones de farmacos que los contienen.
NO20062040L (no) Modulatorer for atp-bindende kassett-transportere inneholdende cykloalkyl eller pyranylgrupper
PE20040771A1 (es) Derivados de fluoroglicosidos heterociclicos como inhibidores del transportador de glucosa dependiente de sodio
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
NO20052543L (no) 3-aminopyrrolidinderivater som modulatorer av kjemokinreseptorer.
EA200100022A1 (ru) Композиции с контролируемым высвобождением пароксетина
ATE149999T1 (de) Monofluorierte derivate von n-propargyl-1- aminoindan und deren verwendung als monoamino- oxidaseinhibitoren
ATE317226T1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
TR200100754T2 (tr) Glausomanın tedavi edilmesi için serotonerjik 5HT2.
ES2176252T3 (es) Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
CY1110399T1 (el) Ρυθμιστες της τετραϋδροπυρανυλο κυκλοπεντυλο τετραϋδροπυριδοπυριδινης για την ενεργοτητα των υποδοχεων των χημειοκινων
ATE226247T1 (de) Menschliche neuronale nikotin-acetylcholin- rezeptor-verbindungen und methoden ihres einsatzes
CO4700289A1 (es) Antagonistas de taquicinina amida que tienen actividad antagonista de taquicinina
AU4337289A (en) Fluoro substituted benzocycloheptapyridine compounds, compositions and methods of use
DK0530087T3 (da) Hidtil ukendte naphthylethylurinstof- og naphthylethylthiourinstofforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
GT199800013A (es) Sulfonamidas vinculadas con n de tioesteres heterociclicos.
PT799206E (pt) Derivados de aril- e heteroaril-sulfonamida processo para a sua preparacao e sua utilizacao como antagonistas da endotelina
NO304983B1 (no) Nye fosfinyloksymetylketoner, farmas°ytisk sammensetning og anvendelse derav
CO2022018446A2 (es) Compuestos de piperidina sustituida y su uso
ES2150039T3 (es) Benzonitrilos como 5-ht agonistas y antagonistas.
TR200002896T2 (tr) Kalsilitik Bileşimler
ES2160951T3 (es) Derivados de distamicina, procedimiento para la preparacion de los mismos y su uso como agentes antitumorales y antiviricos.
ES2155660T3 (es) Derivados de bencimidazol, de benzoxazol y de benzotiazol, utilizables como inhibidores de la interleuquina 1beta.
IL65802A (en) 1-(3-fluoro-2-pyridinyl)piperazine and salts thereof,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 882719

Country of ref document: ES